Menu

Many Editors of US Medical Journals Receive Industry Funding

The authors of two new studies on the payments suggest stricter guidelines are needed.

Nov 8, 2017
Shawna Williams

ISTOCK, APPLEUZRRead through a paper in a reputable medical journal, and chances are that if its authors have a conflict of interest related to its contents—if they receive licensing payments for the technology described, for example, or research funding from industry—that information will be disclosed. But if the journal editor who decided to publish the paper has such a conflict of interest, that information is unlikely to be so easy to find.

In two studies published late last month in PeerJ (October 20) and The BMJ (October 26), researchers ran the names of editors of 35 (PeerJ) and 52 (BMJ) top US-based medical journals through the Open Payments database and found that the majority—63 percent of physician-editors in the PeerJ study, and just over half of higher-ranking editors in the BMJ study—had received industry payments in recent years.

STAT notes that in the BMJ report, the median take among the editors receiving industry funds in 2014 was just $11. However, two received more than $1 million each.

“[J]ournal editors are the ones who choose which manuscripts are sent out for peer review, who those peer reviewers are, and ultimately decide what gets published and what doesn’t. Because of their large role in shaping science, the biases of journal editors should be under closer scrutiny,” Victoria Wong, an author of the PeerJ study, tells Retraction Watch.

Wong adds, “The more funds that come from industry, the greater the likelihood that editorial decisions are not objective. It is unfortunate that we’re discussing the incomes of the very people who are the gatekeepers of the medical research that drives health care policy and expenditure, yet our current system does not think it important enough to provide them with a dedicated and unbiased source of income to do this job.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.